Esperion Therapeutics, Inc. · NASDAQ:ESPR
Esperion Therapeutics — Investor Presentation (April 2020)
33 slides from Esperion Therapeutics's investor presentation, Apr 9, 2020
Slide 1: Esperion April 2020 Corporate Overview
ESPERION April 2020 CORPORATE OVERVIEW
Slide 2: Safe Harbor Forward-Looking Statements
SAFE HARBOR FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the clinical development and commercialization plans for bempedoic acid tablet and the bemp
Slide 3: Esperion Company Update April 2020
Esperion Company Update April 2020 Europe: •NILEMDO™ (bempedoic acid) Tablet & NUSTENDI™ (bempedoic acid and ezetimibe) Tablet European Commission Approved United States: •NEXLETOL™ (bempedoic acid) Tablet & NEXLIZET™ (bempedoic acid and ezetimtibe) Tablet FDA Approved •Commercial Launch and Availab
Slide 4: We are open for business
We are open for business… ESPERION is now a research and commercial company focused on lipid management for Everybody
Slide 5: European Approvals & Commercialization NILEMDO and NUSTENDI
EUROPEAN APPROVALS COMMERCIALIZATION NILEMDO™ and NUSTENDI™ &
Slide 6: Proudly Announcing Two European Approvals
PROUDLY ANNOUNCING TWO EUROPEAN APPROVALS PARTNER DAIICHI SANKYO EUROPE POISED FOR INTRODUCTION NEXT QUARTER 6 © 2020 Esperion Therapeutics, Inc. All Rights Reserved NILEMDO™ (bempedoic acid) Tablet Lowered LDL-C Up to 28%* NUSTENDI™ (bempedoic acid and ezetimibe) Tablet Lowered LDL-C by a Mean of 3
Slide 7: Additional European Label Highlights for NILEMDO & NUSTENDI
xFor the first time in almost 20 years, non-statin once-a-day tablets with significant LDL-C lowering efficacy will be available across Europe to fight bad cholesterol ADDITIONAL EUROPEAN LABEL HIGHLIGHTS FOR NILEMDOTM & NUSTENDITM xThe term ”Statin Intolerance” is recognized and used throughout bot
Slide 8: DSE Preparing to Make NILEMDO & NUSTENDI Commercially Available
DSE PREPARING TO MAKE NILEMDO™ & NUSTENDI™ COMMERCIALLY AVAILABLE Daiichi Sankyo Europe (DSE) IN EUROPE IN Q3 • Commercial organization of more than 1,000 professionals focused on the cardiovascular portfolio including Lixiana, Effient and Olmesartan Deep expertise in reimbursement, distribution and
Slide 9: U.S. Approvals & Commercialization
U.S. APPROVALS & COMMERCIALIZATION NEXLETOL™ Now Available in Pharmacies NEXLIZET™ Available in Pharmacies July 2020
Slide 10: Managed Care Access Goals Achieved
MANAGED CARE ACCESS GOALS ACHIEVED EXCEEDS 50% COMMERCIAL COVERAGE AND 20% MEDICARE COVERAGE* • Reminiscent of our industry at its best: Managed care success results from conscientious pricing, positioning and collaborating with payors and PBMs • Parity Pricing for NEXLETOL™ and NEXLIZET™ • Majority
Slide 11: NEXLETOL and NEXLIZET FDA Approved in U.S. – February 2020
NEXLETOL™ AND NEXLIZET™ FDA APPROVED IN U.S. – FEBRUARY 2020 HELPING APPROPRIATE PATIENTS ACHIEVE THEIR LDL-C GOALS NEXLETOL™ is the first oral, once-daily, non-statin LDL-C lowering medicine approved since 2002 for indicated patients NEXLETOL Launching March 2020 NEXLIZET™ is the first non-statin,
Slide 12: Answering Healthcare Providers' Call
ANSWERING HEALTHCARE PROVIDERS’ CALL HELPING TO GET MORE INDICATED PATIENTS TO LDL-C GOAL Available March 30, 2020 Available July 2020 NEXLETOL™ and NEXLIZET™ are each indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hyperc
Slide 13: Fits into LDL-C Treatment Armamentarium
FITS INTO LDL-C TREATMENT ARMAMENTARIUM MAXIMALLY NEXLETOL™ (bempedoic acid) tablets Appropriate patients on maximally tolerated statin dose who still need additional LDL-cholesterol lowering TOLERATED STATINS Indica ed for adult patients wi ASCVD or aximally statins Patients whose high cholesterol
Slide 14: Confident in Manufacturing and Supply Capacity
CONFIDENT IN MANUFACTURING AND SUPPLY CAPACITY AND SUPPLY TO SUPPORT LAUNCH AND FUTURE DEMAND NEXLETOL™ (30-ct bottles) is now available on pharmacy shelves and at wholesaler warehouses across the US Samples (7-day blister packs) at our third-party distributor available for HCPs upon request Confide
Slide 15: Strategically-Built, Healthcare Provider-Facing Team
STRATEGICALLY-BUILT, HEALTHCARE PROVIDER-FACING TEAM DEPLOYING FOR A SUCCESSFUL VIRTUAL LAUNCH TARGET AUDIENCE IDENTIFIED • Over 36,000 healthcare providers who write 40% of all LDL-C lowering medicine prescriptions EXPERTS READY TO GO • 290 industry tenured territory managers with an average of 13
Slide 16: Committed to a Conscientious (and Virtual) Launch
COMMITTED TO A CONSCIENTIOUS (AND VIRTUAL) LAUNCH Initial launch will be through virtual engagement including personalized emails, virtual physician trainings, welcome kits, and other tactics Over 100 KOLs a part of Virtual Speaker Bureau utilizing smartcasts and webcasts for HCP peer-to-peer educat
Slide 17: A Virtual Multichannel Approach to Educate and Support Providers
A VIRTUAL MULTICHANNEL APPROACH TO EDUCATE AND SUPPORT HEALTHCARE PROVIDERS Advocacy Smartcasts and Webcasts DTC Launch Readiness Ensure consistent commnication across key stakeholders Digital Media Patient Access Virtual Congress 17 © 2020 Esperion Therapeutics, Inc. All Rights Reserved
Slide 18: Key Metrics and Beyond: What to Expect for NEXLETOL Launch
KEY METRICS AND BEYOND WHAT TO EXPECT AND FEATURES FOR NEXLETOL™ LAUNCH Key Features x Products that fill unmet need for affordable medicines for millions of indicated patients Key Metrics x Total prescriptions filled/dispensed, NBRx, CBRx, market share performance, and other metrics First prescript
Slide 19: More Than 1.8M US Patients on Therapy at Peak
mary research supports recast to h MORE THAN 1.8M US patients on therapy at peak Data on File: ZS Associates Market Sizing and Forecasting Project, December 2019. N=350 Physicians © 2020 Esperion Therapeutics, Inc. All Rights Reserved
Slide 20: Building Long-Term Shareholder Value
BUILDING LONG-TERM SHAREHOLDER VALUE
Slide 21: Esperion: Fully Funded Through Profitability
ESPERION: FULLY FUNDED THROUGH PROFITABILITY Near-Term Capital Proceeds from Collaboration Agreements • EU licensing agreement with Daiichi Sankyo Europe (DSE) • $900 million in total milestones • Tiered royalties on net sales between 15% – 25% Cash as of 4Q2019: $201.7 million • • Milestone payment
Slide 22: Building Sustainable Shareholder Value in 2020
BUILDING SUSTAINABLE SHAREHOLDER VALUE IN 2020 x x x x x o o o o FDA Approval of NEXLETOL ™ and NEXLIZET ™ Positive EU CHMP Opinions Received $25M Milestone Payment from Oberland NEXLETOL™ Commercial Launch in the U.S. EU Approval of NILEMDO ™ and NUSTENDI™ Potential ROW Agreements (2Q) NEXLIZET™ Co
Slide 23: Our shared future looks bright.
Our shared futurelooks bright. © 2020 Esperion Therapeutics, Inc. All Rights Reserved
Slide 24: Previously Announced Information About Our Products
PREVIOUSLY ANNOUNCED INFORMATION ABOUT PRODUCTS OUR
Slide 25: Millions of US Patients Unable to Achieve LDL-C Goals
MILLIONS OF US PATIENTS UNABLE MORE NON-STATIN LDL-C LOWERING NEEDS TO BE DONE TO ACHIEVE LDL-C GOALS Source ZS Associates primary and secondary research. Sep-Oct 2018. Primary research N = 350 healthcare practitioners © 2020 Esperion Therapeutics. Inc. All Rights Reserved 25
Slide 26: NEXLETOL: Significant Additional LDL-C Lowering Efficacy
NEXLETOL™: SIGNIFICANT ADDITIONAL LDL-C LOWERING EFFICACY IN PATIENTS ON MAXIMALLY TOLERATED STATINS FDA APPROVAL BASED ON ROBUST EVIDENCE FROM TWO PHASE 3 STUDIES IN OVER 3,000 PATIENTS • Average 18% LDL-cholesterol lowering on top of maximally tolerated statin therapy with over 50% of studied pati
Slide 27: NEXLETOL Safety Profile
NEXLETOL™ SAFETY PROFILE • • Contraindications: None Warnings and Precautions: • Hyperuricemia: NEXLETOL may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout. • Tendon Rupture: NEXLETOL is associated with an increased risk of ten
Slide 28: NEXLIZET: Significant Additional LDL-C Lowering Efficacy
NEXLIZET™: SIGNIFICANT ADDITIONAL LDL-C LOWERING EFFICACY IN PATIENTS ON MAXIMALLY TOLERATED STATINS FDA APPROVAL BASED ON ROBUST EVIDENCE FROM PIVOTAL PHASE 3 STUDY IN OVER 300 PATIENTS • 38% mean LDL-cholesterol lowering compared to placebo on top of maximally tolerated statin therapy • USPI notes
Slide 29: NEXLIZET Safety Profile
NEXLIZET™ SAFETY PROFILE • • Contraindication: Known hypersensitivity to ezetimibe tablets Warnings and Precautions: • Hyperuricemia: Bempedoic acid may increase blood uric acid levels, and may lead to the development of gout, especially in patients with a history of gout. • Tendon Rupture: Bempedoi
Slide 30: CLEAR Outcomes Trial Designed to Evaluate CV Risk Reduction
CLEAR OUTCOMES TRIAL DESIGNED TO EVALUATE CV IN HIGH RISK PATIENTS NOT ON BACKGROUND STATIN RISK REDUCTION THERAPY IN 2022 LANDMARK CV OUTCOMES TRIAL DESIGN; TOP-LINE RESULTS EXPECTED Design Key Milestones x x • Q4 2016 study initiated Q3 2019 enrollment completed 2H 2022 results expected (1) 52% Eu
Slide 31: Intellectual Property for Bempedoic Acid
INTELLECTUAL PROPERTY FOR BEMPEDOIC ACID • • Composition of matter through mid-2031(inclusive of available patent term extensions) Various methods of use, manufacturing, and formulation expected to expand coverage through at least 2036 • • • Composition of matter through 2028 (inclusive of available
Slide 32: First Oral, Once-Daily, Non-Statin LDL-C Lowering Medicines Approved in Europe
FIRST ORAL, ONCE-DAILY, NON-STATIN LDL-C LOWERING MEDICINES APPROVED IN EUROPE IN ALMOST TWO DECADES FOR INDICATED PATIENTS The European Commission approved NILEMDO™ for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to
Slide 33: NILEMDO & NUSTENDI Safety Profile
NILEMDO™ & NUSTENDI™ SAFETY PROFILE x NILEMDO was generally well-tolerated in clinical studies. The most commonly reported adverse reactions with NILEMDO during pivotal trials were hyperuricaemia, pain in extremity and anaemia x NUSTENDI was generally well-tolerated in clinical studies. The most com
Esperion Therapeutics — Investor Presentation (April 2020) on 6ix